AU4508199A - Creation of Inventions and Patents with Artificial Intelligence

AU4508199A – Derivatives of 3-(2-oxo-(1,3′)bipyrrolidinyl-3-ylidenemethyl)-cephems
– Google Patents

AU4508199A – Derivatives of 3-(2-oxo-(1,3′)bipyrrolidinyl-3-ylidenemethyl)-cephems
– Google Patents
Derivatives of 3-(2-oxo-(1,3′)bipyrrolidinyl-3-ylidenemethyl)-cephems

Download PDF
Info

Publication number
AU4508199A

AU4508199A
AU45081/99A
AU4508199A
AU4508199A
AU 4508199 A
AU4508199 A
AU 4508199A
AU 45081/99 A
AU45081/99 A
AU 45081/99A
AU 4508199 A
AU4508199 A
AU 4508199A
AU 4508199 A
AU4508199 A
AU 4508199A
Authority
AU
Australia
Prior art keywords
oxo
hydrogen
ocor
compounds
cooch
Prior art date
1998-06-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU45081/99A
Other versions

AU754732B2
(en

Inventor
Paul Hebeisen
Christian Hubschwerlen
Jean-Luc Specklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Basilea Pharmaceutica International Ag Allschwil

Original Assignee
Basilea Pharmaceutica International Ag Allschwil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1998-06-15
Filing date
1999-06-07
Publication date
2000-01-05

1999-06-07
Application filed by Basilea Pharmaceutica International Ag Allschwil
filed
Critical
Basilea Pharmaceutica International Ag Allschwil

2000-01-05
Publication of AU4508199A
publication
Critical
patent/AU4508199A/en

2001-08-23
Assigned to BASILEA PHARMACEUTICA AG
reassignment
BASILEA PHARMACEUTICA AG
Alteration of Name(s) of Applicant(s) under S113
Assignors: F. HOFFMANN-LA ROCHE AG

2002-11-21
Application granted
granted
Critical

2002-11-21
Publication of AU754732B2
publication
Critical
patent/AU754732B2/en

2023-06-15
Assigned to Basilea Pharmaceutica International AG
reassignment
Basilea Pharmaceutica International AG
Request for Assignment
Assignors: BASILEA PHARMACEUTICA AG

Status
Active
legal-status
Critical
Current

2024-06-07
Adjusted expiration
legal-status
Critical

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

C07D501/14—Compounds having a nitrogen atom directly attached in position 7

C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3

C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids

C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3

C07D501/48—Methylene radicals, substituted by hetero rings

C07D501/56—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by carboxylic acids containing hetero rings

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P31/04—Antibacterial agents

Description

WO 99/65920 PCT/EP99/03907 Derivatives of 3-(2-oxo-[1,3′ ]bipyrrolidinyl-3-ylidenemethyl)-cephems The present invention is concerned with new compounds of formula I OR’ / N R 3 N H ‘ – Ne >z- x 0 J-‘ .N N
H
2 N 0 O 0 OR 2 5 wherein
R
1 is hydrogen, C 1 -6-alkyl, optionally substituted by fluoro, or Ca.-6-cycloalkyl;
R
2 is hydrogen or a group selected from -CH2C(=CHR)-COOR, -CH 2 OCOR, -CH(R)OCOR, 10 -CH(R)OCOOR, -CH(OCOR)OCOR, -CH 2
COCH
2 OCOR and R -CH, O 2 0
R
3 is hydrogen or group selected from -CH 2
C(=CH
2 )-COOR,
-COOCH
2 C(=CHR)-COOR, -COOCH 2 OCOR, -COOCH(R)OCOR, -COOCH(R)OCOOR, 15 -COOCH(OCOR)OCOR, -COOCH 2
COCH
2 OCOR, and R\O -COOCH2 O O with the proviso that one of R 2 and R 3 is hydrogen and the other of R 2 and R 3 is different from hydrogen, R is hydrogen or C1-6-alkyl; WO 99/65920 2 PCT/EP99/03907 R is hydrogen or hydroxy,
R
5 is hydrogen or co-hydroxyalkyl; and X is CH or N, as well as pharmaceutically acceptable salts of said compounds and hydrates 5 of the compounds of formula I and of their salts. Compounds of formula A ,OR HH
H
2 N 0 OR 5 A wherein R’ and X are as defined above and R 5 is hydrogen, and pharmaceutically 10 acceptable salts thereof, especially (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxy imino-acetylamino] -8-oxo-3- [(E)-(R)-2-oxo- [1,3′]bipyrrolidinyl-3-ylidene methyl]-5-thia- 1-aza-bicyclo [4.2.0]oct-2-ene-2-carboxylic acid are potent antibacterial agents with activity against methicillin resistant staphylococci, 15 both in vitro and in vivo. However, these compounds have limited solubility, not allowing bolus injections. It is therefore necessary to find derivatives of the compounds A to render these compounds suitable for parenteral and intramuscular application. From J. Med. Chem. (1996), 39(2), 480-6; US patent no. 5 466 811; 20 Bioorganic and Medicinal Chem. Lett. 1997,7,2909-2912; US patent no. 5 610 314 (oxodioxolenyl)methyl carbamates are known to form derivatives of amines e.g. for fibrinogen receptor antagonists, ampicillin, norfloxacin and other pharmaceuticals. Furthermore, 2-(alkyloxycarbonyl)-2-alkylideneethyl esters have been described as prodrugs of carboxylic acids for cephalosporins, 25 J. Antibiot. (1992), 45(8), 1358-64. Both types of derivatives have been used to improve the oral bioavailability of the corresponding drugs. It has now been found that the compounds of formula I exhibit better solubility in water and buffers at physiological pH. In vitro and in vivo they were readily converted to compounds of formula A and can therefore be used 30 for parenteral and intramuscular application forms. The invention is thus also concerned with pharmaceutical preparations containing a compound of formula I and a therapeutically inert carrier.
WO 99/65920 3 PCT/EP99/03907 As used herein “pharmaceutically acceptable salts” useful in this invention include salts derived from metals, salts from amino acids and salts of mineral or organic acids. Examples of preferred metal salts are those derived from the alkali metals, for example, lithium (Li+), sodium (Na
+
) and 5 potassium (K+). Especially preferred is sodium.-Other salts are derived from amino acids such as, for example, salts with arginine or lysine. Examples of salts of mineral acids are for example hydrochlorides, sulphates or phosphates, and examples of salts of organic acids are mesylates (methylsulfonic acid salts), napsylates (naphthtene-2-sulfonic acid salts), besylates o10 (benzenesulfonic acid salts), maleates, salicylates, tartrates, lactates, citrates, benzoates, succinates, acetates and the like. Especially preferred are chlorides, sulfates, phosphates, lactates and mesylates. In the formulas represented herein, when substituents are illustrated as joined to the nucleus a solid line ( – ), indicates that the substituent is in 15 the -orientation, that is, above the plane of the molecule, a broken line ( ” ” ), indicates that the substituent is in the a-orientation, that is, below the plane of the molecule whereas the …… line ( A ) indicates that the bond is either in a- or in 3-orientation. The term “C 1 -alkyl, optionally substituted by fluoro” refers to both 20 straight and branched chain saturated hydrocarbon groups having 1 to 6 and preferably 1 to 4 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, tertiary butyl and the like, these group may be substituted by one or more fluorine atoms as e.g. in fluoromethyl or trifluoromethyl. As used herein, the term “co-hydroxyalkyl” refers to both straight and 25 branched chain saturated hydrocarbon groups as defined above bearing a hydroxy group in the terminal position, e.g. hydroxymethyl, 2-hydroxyethyl, 3 hydroxypropyl, preferably hydroxymethyl. By the term “C 3 .-cycloalkyl” is meant a 3-6 membered saturated carbocyclic moiety, e.g., cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, in 30 particular cyclopentyl. Especially preferred compounds of formula I are the compounds of formula WO 99/65920 4 PCT/EP99/03907 OR / N 3 N H ,R SI, YN S N_” N
H
2 N 0 4 0 OR 2 I-a wherein, R 1
R
2 3 and X are as defined above and R 4 and R 5 are hydrogen, as well as pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I-a and of their salts. 5 Further preferred compounds are epimers and diastereoisomers of formula I-a. Preferred compounds of formula I and formula I-a are compounds wherein R’ is hydrogen, X is N and R 2 is hydrogen and R’ is a group chosen from 10 -CH 2
C(=CH
2
)-COOCH
2 CH,
-COO-CH
2
C(=CHCH
2 CH3)-COOCH 2
CH(CH)
2 , and particularly R
–
0 O0 o 0 0 Further preferred compounds of formula I are compounds wherein R1 15 and R3 are hydrogen, X is N and R2 is a group chosen from -CH2C(=CHCH2CH3)-COOCH2CH(CH3)2, -CH2C(=CH2)-COOCH2CH3, -CH2OCOC(CH3)3, -CH(CH3)OCOCH3, -CH(CH3)OCOOCH2CH3, -CH(OCOCH3)OCOCH3, -CH2COCH2OCOCH3, and R 0 20 Especially preferred compounds of formula I and I-a are (6R,7R)-7-[(Z)- 2 -(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetyl amino] -3- [(E)-(R)-1′-(5-methyl-2-oxo- [1,31 dioxol-4-ylmethoxycarbonyl)-2-oxo [1,3′]bipyrrolidinyl-3-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo [4.2.0]oct-2-ene 2-carboxylic acid 25 (6R,7R)-7- [(Z)-2-(5-amino- [1,2,4]thiadiazol-3-yl)-2-hydroxyimino acetylamino] -3-[(E)-(R)-1′-(5-ethyl-2-oxo- [1,3]dioxol-4-ylmethoxycarbonyl)-2- WO 99/65920 PCT/EP99/03907 5 oxo- [1,3′]bipyrrolidinyl-3-ylidenemethyl] -8-oxo-5-thia- 1-aza-bicyclo [4.2.0] oct-2 ene-2-carboxylic acid sodium salt (1:1) (6R,7R)-7-[(Z)- 2 -(5-Amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino acetylamino]-3- [(E)-(R)- 1′-(2-oxo-5-propyl -[1,3] dioxol-4-ylmethoxycarbonyl)-2 5 oxo- [1,3′]bipyrrolidinyl-3-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2 ene-2-carboxylic acid sodium salt (1:1) (6R,7R)-7-[(Z)-2-(5-amino-[1, 2
,
4 ]thiadiazol-3-yl)-2-hydroxyimino-acetyl amino]-3- [(E)-(R)- 1′-( 5-isopropyl-2-oxo -[1,3]dioxol-4-ylmethoxycarbonyl)-2 oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyll]-8-oxo-5-thia-1-aza-bicyclo [4.2.0]oct-2 10 ene-2-carboxylic acid sodium salt (1:1) (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetyl amino]-3-[(E)-(R)-1′-( 5-tert-butyl-2-oxo-[1,3]dioxol-4-ylmethoxycarbonyl)-2 oxo-[1,3′]bipyrrolidiny1-3-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2 ene-2-carboxylic acid sodium salt (1:1) 15 (6R,7R)-7-[(Z)-2-(5-Amino- [1,2,4]thiadiazol-3-yl)-2-hydroxyimino acetylamino]-3-[(E)-(R)-1′-
(E-
2 -isobutoxycarbonyl-pent-2-enyloxycarbonyl)-2 oxo -[1 ,3′]bipyrrolidinyl-3-ylidenemethyl] -8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct 2-ene-2-carboxylic acid sodium salt (1:1) (6R,7R)-7-[(Z)- 2 -(5-Amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino 20 acetylamino]-3-[(E)-(R)-1′-(2-ethoxycarbonyl-allyl)-2-oxo-[1,3′]bipyrrolidinyl-3 ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt (1:1) (6R,7R)-7-[(Z)-2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino acetylamino]-3-[(E)-5′-hydroxymethyl-1′-(5-methyl-2-oxo-[1,3]dioxol-4 25 ylmethoxycarbonyl)-2-oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl]l-8-oxo-5-thia-l aza-bicyclo[4.2.01]oct-2-ene-2-carboxylic acid sodium salt (6R,7R)-7-[(Z)-2-(5-amino- [1,2,4]thiadiazol-3-yl)-2-hydroxyimino acetylamino]-3-[(E)-(3’S,4’S)- and -(3’R,4’R)-4′-hydroxy-1′-(5-methyl-2-oxo [1,3]dioxol-4-ylmethoxycarbonyl)-2-oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl]-8 30 oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt The compounds of formula I and I-a as well as their salts can be hydrated. The hydration can be effected in the course of the manufacturing process or can occur gradually as a result of hygroscopic properties of an initially anhydrous product. 35 The compounds of the present invention are useful as antibiotics having potent and broad antibacterial activity; especially against methicillin resistant Staphylococci (MRSA) and Pseudomonas aeruginosa.
WO 99/65920 6 PCT/EP99/03907 The products in accordance with the invention can be used as medicaments, for example, in the form of pharmaceutical preparations for parenteral administration, and for this purpose are preferably made into preparations as lyophilisates or dry powders for dilution with customary 5 agents, such as water or isotonic common salt or carbohydrate (e.g. glucose) solution. Depending on the nature of the pharmacologically active compound the pharmaceutical preparations can contain the compound for the prevention and treatment of infectious diseases in mammals, humans and non-humans. A 10 daily dosage of about 10 mg to about 4000 mg, especially about 50 mg to about 3000 mg, is usual, with those of ordinary skill in the art appreciating that the dosage will depend also upon the age, conditions of the mammals, and the kind of diseases being prevented or treated. The daily dosage can be administered in a single dose or can be divided over several doses. An average 15 single dose of about 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg, and 2000 mg can be contemplated. The compounds of the formula I and I-a in accordance with the invention as well as their pharmaceutically acceptable salts, hydrates, or readily hydrolyzable esters can for example be prepared in accordance to procedures 20 given below: Compounds of formula I and I-a wherein R 2 is hydrogen and R 3 is a group
-COOCH
2 C(=CHR)-COOR, -COOCH 2 OCOR, -COOCH(R)OCOR, -COOCH(R)OCOOR, -COOCH(OCOR)OCOR, -COOCH 2
COCH
2 OCOR or R -oo JO 0 25 can be prepared according to Scheme 1 by acylation of compounds of formula A with the corresponding carbonic acid 4-nitrophenyl ester.
WO 99/65920 7 PCT/EP99/03907 Scheme 1 R H +
H
2 H2 O A 2. Na-ethylcaproate in DMSO 02 H2 O Na wherein R’ and R are as defined above and Y is a group
-CH
2 C(=CHR)-COOR,
-CH
2 OCOR, -CH(R)OCOR, -CH(R)OCOOR, 5 -CH(OCOR)OCOR,
-CH
2 CO CH 2 OCOR, or R For the preparation of compounds of formula I and I-a wherein R is
-CH
2
C(=CH
2 )-COOR a compound of formula A is reacted with 2-(4-nitro 10 phenoxycarbonyloxymethyl)-acrylic acid ethyl ester. This reaction proceeds with loss of carbon dioxide, cf. scheme 2: WO 99/65920 8 PCT/EP99/03907 Scheme 2 NOR I H S N2 N N
H
2 N O 0 0 OO\ 1. 0 2 N OOO OR 0 2. Na-ethylcaproate in DMSO NOR S I H NOR
H
2 N 0 0 O ONa The synthesis of the compounds of formula I and I-a, wherein R 3 is 5 hydrogen, (Scheme 3) is accomplished via alkylation of the carboxylate, preferably at the stage of the fully protected compound of formula A. Protecting groups for R 1 are preferably, the trityl and in position R’ tert.
butyloxycarbonyl (BOC). Removal of the tert.-butyloxycarbonyl and trityl protecting groups is accomplished by conventional methods and the desired 10 compounds of formula I and I-a are isolated as the hydrochloride salts by precipitation from dioxane.
WO 99/65920 9 PCT/EP99/03907 Scheme 3 TIOR 1TH BO C H2 O H 1. R 2 Br 2. TFA 3. HCI R 1TH H2+.Cl H2 O R 2 wherein R’ is C1-6-alkyl, optionally substituted by fluoro, or C3 cycloalkyl or a protecting group, preferably trityl, and BOC is tert.
5 butyloxycarbonyl Compounds of formula A are known compounds and can be prepared according to the methods described in EP appl. no. 97119528.4. The alkylating agents, i.e. the compounds R 2 Br or R 2 Cl are known compounds, some are commercially available. 10 The following examples further illustrate the invention, however, without limiting its scope. Examples 1.1. Synthesis of (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2 hydroxyimino-acetylamino]-3-[(E)-(R)-l’.(5-methyl-.2.-oxo-[1,3]dioxol-4. 15 ylmethoxycarbonyl)-2-oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl].-8-oxo. 5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid OH / 0 S S NO Of,0 ”
H
2 N O a O 0 O-Na. To a solution of 13.2 g (44.72 mmol) of carbonic acid 5-methyl-2-oxo [1,3]dioxol-4-ylmethyl ester 4-nitro-phenyl ester in 200 ml of WO 99/65920 10 PCTIEP99/03907 dimethylsulfoxide are added 20.0 g of (6R,7R)-7-[(Z)-2-(5-amino [1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetylamino]-8-oxo-3- [(E)-(R)-2-oxo [1,3′]lbipyrrolidinyl-3-ylidenemethyl] -5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2 carboxylic acid. The mixture is stirred under argon at room temperature for 4 5 hours and 1000 ml of acetone are added. The slightly turbid solution is clarified by filtration over a fluted filter. To the clear motherliquour are added 34.0 ml (34 mmol) of a 1N solution of sodium-2-ethylcaproate in acetone at room temperature during 20 minutes. The slightly yellow suspension is stirred for 10 minuntes at room temperature, the solid is collected by filtration, 10 washed with 1000 ml of acetone and 1000 ml of n-pentane and dried under high vacuum. The product is suspended in 600 ml of acetone and stirred at room temperature for 2 hours. The product is collected by filtration and dried under high vacuum to yield 23.94 g of the title compound as an off-white powder. 15 MS(ISP): M+H 4 =691.3;M+NH4+=708.2;M+Na’=713.1 In a similar manner, the following carbamates are prepared from the corresponding mixed carbonates: 1.2. ( 6
R,
7
R)-
7 -[(Z)-2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino. acetylamino]-3-[(E)-(R)-1′-(5-ethyl-2-oxo-[1,3]dioxol-4-ylmethoxy 20 carbonyl)-2-oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl].8.-Soxo-.5.-thia-1. aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt (1:1) .OH N H 0 N N S S N O 0N- O O O O O O O- Na* MS (ISP): M+H =705.2,M+NH 4 =722.3,M+Na =727.2 1.3. (6R,7R)-7-[(Z)-2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino 25 acetylaminol-3-[(E)-(R)-1′-(2-oxo-5-propyl -[1,3]dioxol-4-ylmethoxy carbonyl)-2-oxo-[ 1,3′]bipyrrolidinyl-3-ylidenemethyll-8-oxo-5-thia-1 aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt (1:1) OH N’ 0
H
2 N- f O S-N 00JNN Og 0 0 0 0 0- + Na WO 99/65920 11 PCTIEP99/03907 MS (ISP): M+H’=719.3,M+NH 4 =736.2,M+Na’=741.2 1.4. (6R,7R)-7-[(Z)-2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino acetylamino-3-[(E)-(R)-1′-( 5-isopropyl-2-oxo -[1,3]dioxol-4-ylmethoxy carbonyl)-2-oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl]-8-oxo-5-thia-1 5 aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt (1:1) ,OH N O N N S N
H
2 N(O s- – N- JO 0 0 0 + 0 Na MS (ISP): M+H 4 =719.3,M+NH 4 =736.2,M+Na’=741.2 1.5. (6R,7R)-7-[(Z)-2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino acetylamino-3-[(E)-(R)-1′-( 5-tert-butyl-2-oxo-[1,3]dioxol-4-ylmethoxy 10 carbonyl)- 2 -oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl]-8-oxo-5-thia-1 aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt (1:1) ,OH NO NO O H N-– WO 99/65920 13 PCT/EP99/03907 A mixture of 2.60 g of 2-hydroxymethyl-acrylic acid ethyl ester (0.020 mol) and 4.0 g of 4 -nitrophenyl-chloroformate (0.020 mol) in 70 ml dichloromethane is treated with a solution of 5.5 ml (0.030 mol) of ethyl-diisopropylamine in 55 ml of dichloromethane at 0 0 C for two hours. The mixture is hydrolyzed with 10% 5 potassium bicarbonate, the phases are separated and the product contained in the organic phase is purified by chromatography on silica gel using a 4:1 mixture of n-hexane and ethyl acetate as eluent. The product fractions are collected and evaporated yielding 3.5g (60%) of the title compound as a white crystalline solid with melting point 42-43 0 C after crystallisation from t 10 butylmethyl ether and n-hexane. b) 2
-(
4 -Nitro-phenoxycarbonyloxymethyl).-pent-.2.enoic acid isobutyl ester 0 0 0 15 is prepared according to the procedure described above. A yellowish oil is obtained. MS (EI): M+H =352 M-C 4
HO
7 0 = 278 Example 2 20 2.1. a) Synthesis of (6R, 7 R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-.2. trityloxyimino-acetylamino]-3- [(E)-(R)-1′-tert-butoxycarbonyl-2.-oxo [1,3′]bipyrrolidinyl-3-ylidenemethyl]8-oxo-5-thia-l-aza bicyclo[ 4
.
2 .0]oct-2-ene-2-carboxylic acid Ph 3 ,0 N N S H N S – N O N N 0 0 0 OH 25 To a solution of 1.67g (1.965 mmol) of (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thia diazol-3-yl)-2-trityloxyimino-acetylamino]-8-oxo-3-[(E)-(R)-2-oxo-[1,3′]bi pyrrolidinyl-3-ylidenemethyl] -5-thia-1-aza-bicyclo [4.2.0]oct-2-ene-2-carboxylic acid hydrochloride salt (1:2) in 20.0 ml of dimethylformamide are added 0.56 ml (4.00 mmol) of triethylamine and 0.554 g di-tert-butyldicarbonate and the WO 99/65920 14 PCT/EP99/03907 mixture is stirred at room temperature for 1.5 hours. The mixture is diluted with 500 ml of ethyl acetate and 100 ml water. The pH is adjusted to 2 by the addition of 1N hydrochloric acid. The phases are separated and the organic phase is washed twice with 100 ml of water, clarified by filtration over a fluted 5 filter and concentrated. 100 ml of diethyl ether are added and the resulting suspension is stirred at room temperature for 1 hour. The solid is collected by filtration, washed with diethyl ether and dried, yielding 1.31g (76% ) of the title compound as a beige powder. MS (ISP): (M+H)=877.4 (M+NH,)=894.4 (M+Na)=899.4 10 b) Synthesis of ( 6
R,
7 R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-.yl)-.2.
hydroxyimino-acetylamino]-8-oxo-3-[(E)-(R)-2-oxo-[1,3′]bipyrrolidinyl 3-ylidenemethyl]-5-thia–aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (E)-2-isobutoxycarbonyl-pent-2-enyl ester hydrochloride (1:1.6) NOH S N N N 0 N HNO O
H
2 N 0O O 0 0 CI 0 – 0 l 15 O To a solution of 0.150 g (0.171 mmol) of (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thia diazol-3-yl)-2-trityloxyimino-acetylamino]-3-[(E)-(R)-1′-tert-butoxycarbonyl-2 oxo- [1,3′]bipyrrolidinyl-3-ylidenemethyl]8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2 ene-2-carboxylic acid in 1 ml of dimethylsulfoxide are added 18.7 mg of (0.163 20 mmol) 1,1-3,3-tetramethyl guanidine and 64 mg (0.257 mmol) of isobutyl (Z)-2 (bromomethyl)-2-pentenoate, and the mixture is stirred at room temperature for 20 minutes. The solvent is evaporated under high vacuum and the residue purified by chromatography on MCI-gel using a gradient of 40 to 100% of acetonitrile in water as eluent. The product fractions are collected and the 25 organic solvent is removed by evaporation. The product is extracted from the remaining aqueous phase with dichloromethane. The combined organic phases are dried over magnesium sulfate, evaporated to dryness and triturated with tert-butylmethyl ether to yield 130 mg (0.125 mmol) beige crystals with melting point 158-159 0 C which are dissolved in 1.2 ml of dichloromethane. To 30 this solution are added 0.0366 ml (0.23 mmol) of triethylsilane and 0.38 ml of trifluoroacetic acid at 0 0 C and the mixture is stirred for 1 hour. To the WO 99/65920 15 PCT/EP99/03907 resulting clear solution 2.0 ml of dioxane are added and the mixture is concentrated under vacuum. The residue is dissolved in 2.0 ml of dioxane and 0.182 ml of a 1.9 N solution of hydrochloric acid in dioxane are added with stirring at room temperature. The precipitate is collected by filtration washed 5 with dioxane and acetone and dried yielding 85 mg of the title compound as beige crystals melting at 139-140C (dec). HPLC: 99.%(area) MS: M+H*=703.3 In a similar manner the following prodrug-ester compounds are prepared starting from the corresponding alkyl halides: 2.2. (6R,7R)-7-[(Z)- 2 -(5-amino-[1,2,4]thiadiazol-3-yl)-2.-hydroxyimino. 10 acetylamino]-8-oxo-3-[(E)-(R)-2-oxo-[1,3′]bipyrrolidinyl-.3.-ylidene methyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2 dimethyl-propionyloxymethyl ester hydrochloride NOH N N S N SN
H
2 N 0 ?0 CL O MS (ISP): M+H’=649.3 15 2.3. (6R,7R)-7-[(Z)- 2
-(
5 -amino-[1,2,4]thiadiazol-3-yl)-2.-hydroxyjmino. acetylamino]-8-oxo-3-[(E)-(R)2-oxo-[1,3’bipyrrolidinyl-.3.-ylidene. methyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2.-carboxylic acid 5-methyl 2-oxo-[1,3]dioxol-4-ylmethyl ester hydrochloride (1:1.5) NOH N S
H
2 N 0 00 C 0 c- /-o 0 20 MS (ISP): M+H+=647.3 WO 99/65920 16 PCTIEP99/03907 2.4. 1:1 Mixture of ( 6 R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol3yl).2 hydroxyimiiuo-acetyaiino-8oxo-3-(E)(R).2oxo4 1,3′]bipyrrolidinyl 3-ylidenemethy1-5-thia–azabicyco[4.2.]oct2ene2crboxyic acid (R)- and (S)-1-acetoxy-ethyl ester hydrochloride (1:1.2) N’ OH SN IN SH N0
H
2 N 0 0 MS (ISP): M+H*=621.3 2.5. 1:1 Mixture of (6R,7R)-7-[ (Z)-2-(5-amino-[ l,2,4lthiadiazol-3-yl)-2 hydroxyimino-acetylamno-8-oxo-3.[ (E)-(R)-2-oxo-[1,3’Ibipyrrolidinyl 3 -ylidenemethylI-5-thia-1-aza-bicyclo[4.2.oct2ene2crboxlic acid 10 (R)- and (S)-1-ethoxycarbonyloxy-ethyl ester hydrochloride (1:1.4) N’ OH SNN: N N
H
2 N 0Q 0 0 0\ MS (ISP): M+H+=651.2 2.6. 1:1 Mixture of (6R,7R)-7-[ (Z)-2-(5-amino-[ 1,2,4lthiadiazol-3-yl)-2 15 hydroxyimino-acetylanmino-8-oxo-3-[ (E)-(IR)-2-oxo-[1,3’Ibipyrrolidinyl 3 -ylidenemethylI-5-thia-l-aza-bicyco[4.2.oct2ene2cboxlic acid (R)- and (S)-l-acetoxy-2-oxo-propyl ester hydrochloride (1:1.4) N* OH SN IN ~S
H
H N 0 C-
H
2 0 0 0 NCI MS (ISP): M+H*=649 20 2.7. (6R,7R)-7-[ (Z)- 2 -(5-Amino-[1,2,4]thiadiazol-3-y1)-2-hydroxyimino.
WO 99/65920 17 PCT/EP99/03907 methyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 3 acetoxy-2-oxo-propyl ester hydrochloride (1:1.65) N’.OH N 0 H S ” , ” ‘ N N N
H
2 N 0C 0 0
CI
O’k 0 MS (ISP): M+H=649.2 5

Claims (10)

1. Compounds of formula I OR 1 / N3 N N H S’s1, 1rN S N x 0 ?N ):-=X 21< H 2N O O 0 OR 2 wherein 5 R is hydrogen, C 1 -alkyl, optionally substituted by fluoro, or C 3 . 6 cycloalkyl; R 2 is hydrogen or a group selected from -CH 2 C(=CHR)-COOR, -CH 2 OCOR, -CH(R)OCOR, -CH(R)OCOOR, -CH(OCOR)OCOR, -CH2COCH 2 OCOR and R -OH0 10 -CH2 0 R is hydrogen or group selected from -CH 2 C(=CH2)-COOR, -COOCH 2 C(=CHR)-COOR, -COOCH 2 OCOR, -COOCH(R)OCOR, -COOCH(R)OCOOR, -COOCH(OCOR)OCOR, -COOCH 2 COCH 2 OCOR, and R 15 -COOCH2"O O 15 with the proviso that one of R 2 and R 3 is hydrogen and the other of R 2 and R 3 is different from hydrogen, R is hydrogen or C1- 6 -alkyl; R 4 is hydrogen or hydroxy, 20 R is hydrogen or o-hydroxyalkyl; and X is CH or N, as well as pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I and of their salts. WO 99/65920 19 PCT/EP99/03907 2.. Compounds according to claim 1 of formula I-a OR / N 3 S N IAz N S N /'R3 2N 0 A74 0 OR 2 I-a wherein R 1 , R', R' and X are as defined in claim 1 and R 4 and R 5 are hydrogen, 5 as well as pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I-a and of their salts. 3. Compounds according to claim 1 or 2, wherein R' is hydrogen, X is N, R 2 is hydrogen and R' is a group -COO-CH 2 C(=CHCH 2 CH 3 )-COOCH 2 CH(CH,) 2 , 10 -CH 2 C(=CH 2 )-COOCH 2 CH 3 , or R -cOO o O 0 4.. Compounds according to claim 1 or 2 wherein R' and R 3 are hydrogen, X is N and R 2 is -CH 2 C(=CHCH 2 CH)-COOCH 2 CH(CH 3 ) 2 , 15 -CH 2 C(=CH 2 )-COOCH 2 CH, -CH 2 OCOC(CH) 3 , -CH(CH 3 )OCOCHI 3 , -CH(CH 3 )OCOOCH 2 CH 3 , -CH(OCOCH 3 )OCOCH, -CH 2 COCH 2 OCOCH 3, or R O \OO 5.. The compound according to claims 1 and 2 (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetylamino] 20 3-[(E)-(R)-1'-(5-methyl-2-oxo-[1,3]dioxol-4-ylmethoxycarbonyl)-2-oxo [1, 3 ']bipyrrolidinyl-3-ylidenemethyl-8-oxo-5-thia- 1-aza-bicyclo[4.2.0]oct-2-ene 2-carboxylic acid 6. The compound according to claims 1 and 2 (6R,7R)-7- [(Z)-2-(5-amino-[1, 2 , 4 ]thiadiazol-3-yl)-2-hydroxyimino-acetylamino] 25 3-[(E)-(R)-1'-(5-ethyl-2-oxo-[1,3]dioxol-4-ylmethoxycarbonyl)-2-oxo [l,3']bipyrrolidinyl-3-ylidenemethyll]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene 2-carboxylic acid sodium salt (1:1) WO 99/65920 20 PCT/EP99/03907 7. Compounds as in any one of claims 1 to 6 for use as pharmaceutically active substances, particularly for the treatment and prophylaxis of infectious diseases. 8. A pharmaceutical preparation containing a compound according to any 5 one of claims 1 to 6 and a therapeutically inert carrier, particularly for the treatment and prophylaxis of infectious diseases. 9. The use of the compounds according to any one of claims 1 to 6 in the treatment and prophylaxis of infectious diseases or for the manufacture of medicaments for the treatment and prophylaxis of infectious diseases. 10 *** AU45081/99A 1998-06-15 1999-06-07 Derivatives of 3-(2-oxo-(1,3')bipyrrolidinyl-3-ylidenemethyl)-cephems Active 2024-06-07 AU754732B2 (en) Applications Claiming Priority (5) Application Number Priority Date Filing Date Title EP98110888 1998-06-15 EP98110888 1998-06-15 EP98117099 1998-09-10 EP98117099 1998-09-10 PCT/EP1999/003907 WO1999065920A1 (en) 1998-06-15 1999-06-07 Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems Publications (2) Publication Number Publication Date AU4508199A true AU4508199A (en) 2000-01-05 AU754732B2 AU754732B2 (en) 2002-11-21 Family ID=26149347 Family Applications (1) Application Number Title Priority Date Filing Date AU45081/99A Active 2024-06-07 AU754732B2 (en) 1998-06-15 1999-06-07 Derivatives of 3-(2-oxo-(1,3')bipyrrolidinyl-3-ylidenemethyl)-cephems Country Status (28) Country Link EP (1) EP1087980B1 (en) JP (1) JP3872955B2 (en) KR (1) KR100411915B1 (en) CN (1) CN1136222C (en) AR (1) AR018675A1 (en) AT (1) ATE231871T1 (en) AU (1) AU754732B2 (en) BE (1) BE2014C034I2 (en) BR (2) BRPI9911178B8 (en) CA (1) CA2334568C (en) CO (1) CO5080758A1 (en) DE (1) DE69905162T2 (en) DK (1) DK1087980T3 (en) ES (1) ES2190222T3 (en) FR (1) FR14C0044I2 (en) GT (1) GT199900084A (en) HU (1) HU0105426A3 (en) ID (1) ID27686A (en) IL (1) IL139872A0 (en) LU (1) LU92564I2 (en) MA (1) MA26650A1 (en) NO (1) NO20006350D0 (en) PA (1) PA8475701A1 (en) PE (1) PE20000645A1 (en) PL (1) PL344994A1 (en) SV (1) SV1999000075A (en) TN (1) TNSN99114A1 (en) WO (1) WO1999065920A1 (en) Families Citing this family (9) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title WO2001004127A1 (en) * 1999-07-07 2001-01-18 F. Hoffmann-La Roche Ag Vinylpyrrolidinone derivatives with substituted thiazole ring EP1148140B1 (en) 2000-04-19 2006-10-04 Basilea Pharmaceutica AG Process for the preparation of D-asparagine derivatives US6504025B2 (en) * 2000-05-24 2003-01-07 Basilea Pharmaceutica Ag Process for the preparation of vinyl-pyrrolidinone cephalosporin derivatives DK1606293T3 (en) 2003-03-27 2009-10-05 Basilea Pharmaceutica Ag Cephalosporin in crystalline form EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives AR071318A1 (en) 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag BENZHIDRIL ESTER OF THE ACID (6R, 7R) -7- {2- (5-AMINO- [1,2,4] TIADIAZOL-3-IL) -2 - [(Z) -TRITILOXIIMINO] -ACETILAMINO} -3- [ (R) -1'-TERC-BUTOXICARBONIL-2-OXO- [1,3 '] BIPIRROLIDINIL- (3E) -ILIDENOMETIL] -8-OXO-5-TIA-1-AZA-BICICLO [4.2.0] OCT- 2-ENO-2-CARBOXILICO CRISTALINO; YOUR ELABORATION AND USE WO2010072672A1 (en) 2008-12-24 2010-07-01 Basilea Pharmaceutica Ag New crystal polymorphs of ceftobiprole US9096610B2 (en) 2009-05-25 2015-08-04 Sandoz Ag Method for the production of ceftobiprole medocaril CA2795556A1 (en) 2010-05-10 2011-11-17 Basilea Pharmaceutica International Ltd. Oxidation process for preparing 3-formyl-cephem derivatives Family Cites Families (2) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title ES2281090T3 (en) * 1996-11-06 2007-09-16 Basilea Pharmaceutica Ag DERIVATIVES OF VINILPIRROLIDONA-CEFALOSPORINA. TW415949B (en) * 1996-12-19 2000-12-21 Hoffmann La Roche Vinyl pyrrolidine cephalosporin derivatives with basic substituents 1999 1999-06-07 KR KR10-2000-7014203A patent/KR100411915B1/en not_active IP Right Cessation 1999-06-07 CN CNB998073474A patent/CN1136222C/en not_active Expired - Lifetime 1999-06-07 ES ES99927894T patent/ES2190222T3/en not_active Expired - Lifetime 1999-06-07 AU AU45081/99A patent/AU754732B2/en active Active 1999-06-07 PL PL99344994A patent/PL344994A1/en unknown 1999-06-07 EP EP99927894A patent/EP1087980B1/en not_active Expired - Lifetime 1999-06-07 DK DK99927894T patent/DK1087980T3/en active 1999-06-07 AT AT99927894T patent/ATE231871T1/en active 1999-06-07 BR BRPI9911178A patent/BRPI9911178B8/en not_active IP Right Cessation 1999-06-07 HU HU0105426A patent/HU0105426A3/en unknown 1999-06-07 JP JP2000554745A patent/JP3872955B2/en not_active Expired - Lifetime 1999-06-07 BR BRPI9911178A patent/BRPI9911178C1/en unknown 1999-06-07 ID IDW20002565A patent/ID27686A/en unknown 1999-06-07 WO PCT/EP1999/003907 patent/WO1999065920A1/en active IP Right Grant 1999-06-07 IL IL13987299A patent/IL139872A0/en unknown 1999-06-07 DE DE69905162T patent/DE69905162T2/en not_active Expired - Lifetime 1999-06-07 CA CA002334568A patent/CA2334568C/en not_active Expired - Lifetime 1999-06-11 CO CO99036886A patent/CO5080758A1/en unknown 1999-06-11 AR ARP990102825A patent/AR018675A1/en active IP Right Grant 1999-06-11 PE PE1999000521A patent/PE20000645A1/en not_active Application Discontinuation 1999-06-14 PA PA19998475701A patent/PA8475701A1/en unknown 1999-06-14 GT GT199900084A patent/GT199900084A/en unknown 1999-06-15 TN TNTNSN99114A patent/TNSN99114A1/en unknown 1999-06-15 MA MA25625A patent/MA26650A1/en unknown 1999-06-15 SV SV1999000075A patent/SV1999000075A/en not_active Application Discontinuation 2000 2000-12-13 NO NO20006350A patent/NO20006350D0/en not_active Application Discontinuation 2014 2014-05-15 BE BE2014C034C patent/BE2014C034I2/en unknown 2014-06-11 FR FR14C0044C patent/FR14C0044I2/en active Active 2014-10-01 LU LU92564C patent/LU92564I2/en unknown Also Published As Publication number Publication date FR14C0044I2 (en) 2015-02-20 TNSN99114A1 (en) 2005-11-10 ES2190222T3 (en) 2003-07-16 CA2334568A1 (en) 1999-12-23 AR018675A1 (en) 2001-11-28 BR9911178A (en) 2001-03-13 BRPI9911178B8 (en) 2017-03-07 LU92564I2 (en) 2014-12-01 NO20006350L (en) 2000-12-13 DK1087980T3 (en) 2003-05-26 HU0105426A3 (en) 2002-12-28 PE20000645A1 (en) 2000-07-26 KR20010052866A (en) 2001-06-25 EP1087980A1 (en) 2001-04-04 AU754732B2 (en) 2002-11-21 PL344994A1 (en) 2001-11-19 WO1999065920A1 (en) 1999-12-23 CN1305484A (en) 2001-07-25 ATE231871T1 (en) 2003-02-15 NO20006350D0 (en) 2000-12-13 HU0105426A2 (en) 2002-05-29 IL139872A0 (en) 2002-02-10 GT199900084A (en) 2000-12-05 CA2334568C (en) 2009-02-24 CO5080758A1 (en) 2001-09-25 BE2014C034I2 (en) 2018-08-24 JP3872955B2 (en) 2007-01-24 FR14C0044I1 (en) 2014-07-18 PA8475701A1 (en) 2000-09-29 EP1087980B1 (en) 2003-01-29 BRPI9911178C1 (en) 2021-05-25 CN1136222C (en) 2004-01-28 KR100411915B1 (en) 2003-12-18 DE69905162T2 (en) 2003-12-24 ID27686A (en) 2001-04-19 BR9911178B1 (en) 2013-10-29 MA26650A1 (en) 2004-12-20 DE69905162D1 (en) 2003-03-06 SV1999000075A (en) 2000-05-02 JP2002518401A (en) 2002-06-25 Similar Documents Publication Publication Date Title KR100395985B1 (en) 2004-02-14 Vinyl pyrrolidinone cephalosporins with basic substituents KR20160065871A (en) 2016-06-09 Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative EP0472060A2 (en) 1992-02-26 Antibiotic c-7 catechol-subtituted cephalosporin compounds, compositions, and use thereof HU190878B (en) 1986-11-28 Process for producing ceph-3-eme-4-carboxilic acid derivatives and pharmaceutical compositions containing them EP1087980B1 (en) 2003-01-29 Derivatives of 3-(2-oxo- 1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems CZ282320B6 (en) 1997-06-11 Diastereomer of 1-(isopropoxycarbonyloxy) ethyl ester of (6r, 7r)-7-/2-(2-aminothiazol-4-yl)-2-(z)-(methoxyimino)-acetamido/-3-cephem-4- carboxylic acid, process for preparing thereof, pharmaceutical preparation and its use EP0264091B1 (en) 1992-02-05 3-propenylcephem derivative, preparation thereof, chemical intermediates therein, pharmaceutical composition and use EP0272487A1 (en) 1988-06-29 Cephalosporin derivatives and their crystalline derivatives, process for the preparation of the same, intermediates for use in the synthesis of the same, pharmaceutical compositions comprising the same, and the use of the same for the manufacture of a medicament having valuable therapeutic and preventative properties US6232306B1 (en) 2001-05-15 Derivatives of 3-(2-oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl)-cephams KR0166378B1 (en) 1999-01-15 7-acyl-3-substitued carbamoyloxy)cephem compounds and process for their preparation KR100528305B1 (en) 2005-11-15 New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives JPWO2013002215A1 (en) 2015-02-23 Cephem compound having pyridinium group EP0449515B1 (en) 1995-05-24 Novel cephalosporin intermediates and process for preparing the intermediates and their end products EP0700916B1 (en) 2001-06-20 Cephem compound, process for producing the same, and antibacterial containing the compound MXPA00012391A (en) 2001-11-21 Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems IE51358B1 (en) 1986-12-10 1,2,4-triazinylthiomethyl-3-cephem sulfoxides,process for their preparation and pharmaceutical compositions containing them JP2579472B2 (en) 1997-02-05 Penem compounds KR970004049B1 (en) 1997-03-24 Cephalosporin derivatives JPH0662592B2 (en) 1994-08-17 Intermediate for the production of cefalosporin antibiotics US6294527B1 (en) 2001-09-25 Cephem compounds AU744164B2 (en) 2002-02-14 Cephem compounds JP2002514650A (en) 2002-05-21 Novel cephalosporin compound, production method thereof and antibacterial composition containing the same JPH01261391A (en) 1989-10-18 Cephem derivative KR830001902B1 (en) 1983-09-19 Manufacturing method of waste nisilane derivative KR790001400B1 (en) 1979-10-02 Process for preparing penicillins Legal Events Date Code Title Description 2001-08-23 PC1 Assignment before grant (sect. 113) Owner name: BASILEA PHARMACEUTICA AG Free format text: THE FORMER OWNER WAS: F.HOFFMANN-LA ROCHE AG 2003-03-20 FGA Letters patent sealed or granted (standard patent)
Download PDF in English

None

Contact information